Redeye initiates coverage of Vicore Pharma, a clinical stage biotech name, focusing primarily on rare fibrotic disorders. An investment in Vicore offers highly attractive risk/reward at current levels, in our view. Its lead candidate is pursuing three phase II trials, including an interesting long shot at Covid-19. The compelling case also benefits from a distinguishing ability to bring drugs to market without partners, a solid cash position and strong owners.